Pentixapharm Holding AG annual total liabilities
2021
2022
2023
2024
2025
Pentixapharm Holding AG Total Liabilities Growth & History (PTP)
Pentixapharm Holding AG's total liabilities was €6.8M for fiscal 2025.
View full Pentixapharm Holding AG company overviewPentixapharm Holding AG annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €6.8M | −€11.2M | −62.21% |
| 2024 | 2024-12-31 | €18.0M | −€7.0M | −27.89% |
| 2023 | 2023-12-31 | €24.9M | €9.5M | +61.71% |
| 2022 | 2022-12-31 | €15.4M | €14.2M | +1123.02% |
| 2021 | 2021-12-31 | €1.3M | — | — |
Pentixapharm Holding AG quarterly total liabilities
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €10.0M | −€34,000 | −0.34% |
| Q1 2026 | 2026-03-31 | €9.0M | −€1.1M | −10.95% |
| Q4 2025 | 2025-12-31 | €6.8M | — | — |
| Q3 2025 | 2025-09-30 | €6.2M | — | — |
| Q2 2025 | 2025-06-30 | €10.1M | — | — |
| Q1 2025 | 2025-03-31 | €10.1M | — | — |
Pentixapharm Holding AG total liabilities trends
Between the periods ended 2021-12-31 and 2025-12-31, Pentixapharm Holding AG's total liabilities increased from €1.3M to €6.8M, a change of €5.5M. The latest reported quarter, Q2 2026, shows €10.0M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
reported and calculated total liabilities
TickerStat uses total liabilities reported in company official filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pentixapharm Holding AG source filings ↗